# Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

> **NCT00202930** · PHASE2 · TERMINATED · sponsor: **Jean M. Tersak, M.D.** · enrollment: 4 (actual)

## Conditions studied

- Neuroblastoma
- Opsoclonus-myoclonus

## Interventions

- **DRUG:** anti-CD20 (Rituximab)

## Key facts

- **NCT ID:** NCT00202930
- **Lead sponsor:** Jean M. Tersak, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2008-12
- **Final completion:** 2009-02-05
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Closed early due to low accrual.
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00202930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00202930, "Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00202930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*